Convalescent Plasma and the US Expanded Access Program: A Personal Narrative.

3区 医学 Q2 Medicine Current topics in microbiology and immunology Pub Date : 2024-06-15 DOI:10.1007/82_2024_269
Michael J Joyner
{"title":"Convalescent Plasma and the US Expanded Access Program: A Personal Narrative.","authors":"Michael J Joyner","doi":"10.1007/82_2024_269","DOIUrl":null,"url":null,"abstract":"<p><p>Between early April 2020 and late August 2020, nearly 100,000 patients hospitalized with SARS-CoV2 infections were treated with COVID-19 convalescent plasma (CCP) in the US under the auspices of an FDA-authorized Expanded Access Program (EAP) housed at the Mayo Clinic. Clinicians wishing to provide CCP to their patients during that 5-month period early in the COVID pandemic had to register their patients and provide clinical information to the EAP program. This program was utilized by some 2,200 US hospitals located in every state ranging from academic medical centers to small rural hospitals and facilitated the treatment of an ethnically and socio-economically diverse cross section of patients. Within 6 weeks of program initiation, the first signals of safety were found in 5,000 recipients of CCP, supported by a later analysis of 20,000 recipients (Joyner et al. in J Clin Invest 130:4791-4797, 2020a; Joyner et al. in Mayo Clin Proc 95:1888-1897, 2020b). By mid-summer of 2020, strong evidence was produced showing that high-titer CCP given early in the course of hospitalization could lower mortality by as much as a third (Joyner et al. in N Engl J Med 384:1015-1027, 2021; Senefeld et al. in PLoS Med 18, 2021a). These data were used by the FDA in its August decision to grant Emergency Use Authorization for CCP use in hospitals. This chapter provides a personal narrative by the principal investigator of the EAP that describes the events leading up to the program, some of its key outcomes, and some lessons learned that may be applicable to the next pandemic. This vast effort was a complete team response to a crisis and included an exceptional level of collaboration both inside and outside of the Mayo Clinic. Writing just 4 years after the initiation of the EAP, this intense professional effort, comprising many moving parts, remains hard to completely understand or fully explain in this brief narrative. As Nelson Mandela said of the perception of time during his decades in prison, \"the days seemed like years, and the years seemed like days.\"</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in microbiology and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/82_2024_269","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Between early April 2020 and late August 2020, nearly 100,000 patients hospitalized with SARS-CoV2 infections were treated with COVID-19 convalescent plasma (CCP) in the US under the auspices of an FDA-authorized Expanded Access Program (EAP) housed at the Mayo Clinic. Clinicians wishing to provide CCP to their patients during that 5-month period early in the COVID pandemic had to register their patients and provide clinical information to the EAP program. This program was utilized by some 2,200 US hospitals located in every state ranging from academic medical centers to small rural hospitals and facilitated the treatment of an ethnically and socio-economically diverse cross section of patients. Within 6 weeks of program initiation, the first signals of safety were found in 5,000 recipients of CCP, supported by a later analysis of 20,000 recipients (Joyner et al. in J Clin Invest 130:4791-4797, 2020a; Joyner et al. in Mayo Clin Proc 95:1888-1897, 2020b). By mid-summer of 2020, strong evidence was produced showing that high-titer CCP given early in the course of hospitalization could lower mortality by as much as a third (Joyner et al. in N Engl J Med 384:1015-1027, 2021; Senefeld et al. in PLoS Med 18, 2021a). These data were used by the FDA in its August decision to grant Emergency Use Authorization for CCP use in hospitals. This chapter provides a personal narrative by the principal investigator of the EAP that describes the events leading up to the program, some of its key outcomes, and some lessons learned that may be applicable to the next pandemic. This vast effort was a complete team response to a crisis and included an exceptional level of collaboration both inside and outside of the Mayo Clinic. Writing just 4 years after the initiation of the EAP, this intense professional effort, comprising many moving parts, remains hard to completely understand or fully explain in this brief narrative. As Nelson Mandela said of the perception of time during his decades in prison, "the days seemed like years, and the years seemed like days."

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
康复血浆与美国扩大使用计划:个人经历。
2020 年 4 月初至 2020 年 8 月底期间,美国近 10 万名 SARS-CoV2 感染住院患者在梅奥诊所的 FDA 授权扩大使用计划 (EAP) 赞助下接受了 COVID-19 康复血浆 (CCP) 治疗。在 COVID 大流行初期的 5 个月期间,希望向患者提供 CCP 的临床医生必须向 EAP 计划登记患者并提供临床信息。美国各州从学术医疗中心到小型乡村医院约有 2200 家医院使用了该计划,为治疗不同种族和社会经济阶层的患者提供了便利。在计划启动后的 6 周内,5000 名 CCP 接受者首次出现了安全信号,随后对 20000 名接受者进行的分析也证实了这一点(Joyner 等,发表于《临床研究》J Clin Invest 130:4791-4797, 2020a;Joyner 等,发表于《梅奥临床研究》Mayo Clin Proc 95:1888-1897, 2020b)。到 2020 年仲夏,有确凿证据表明,在住院期间早期给予高滴度 CCP 可将死亡率降低三分之一(Joyner 等,发表于《N Engl J Med》384:1015-1027,2021 年;Senefeld 等,发表于《PLoS Med》18,2021a)。FDA 在 8 月份决定批准医院紧急使用 CCP 时使用了这些数据。本章由 EAP 的主要研究人员以个人身份讲述了该计划的前因后果、一些关键成果以及一些可能适用于下一次大流行的经验教训。这项艰巨的工作是一个完整的团队对危机做出的反应,包括梅奥诊所内外卓越的合作水平。在 EAP 启动仅 4 年后的今天,要写下这篇简短的文章,仍然很难完全理解或充分说明这项由许多活动部分组成的紧张专业工作。正如纳尔逊-曼德拉(Nelson Mandela)在谈到他在狱中数十年对时间的感知时所说,"度日如年,度年如度日"。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
26
审稿时长
>12 weeks
期刊介绍: The review series Current Topics in Microbiology and Immunology provides a synthesis of the latest research findings in the areas of molecular immunology, bacteriology and virology. Each timely volume contains a wealth of information on the featured subject. This review series is designed to provide access to up-to-date, often previously unpublished information.
期刊最新文献
A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19. Alterations of the AKT Pathway in Sporadic Human Tumors, Inherited Susceptibility to Cancer, and Overgrowth Syndromes. Evidence for the Efficacy of COVID-19 Convalescent Plasma. HemoClear: A Practical and Cost-Effective Alternative to Conventional Convalescent Plasma Retrieval Methods. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1